Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018
SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, announced that it has released financial results for the full year ended December 31, 2017 and will host a live conference call and webcast on Monday, April 2 nd
View HTML
Toggle Summary Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive
Advancing 6- and 12- month injectable contraceptive development work carried out to date under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda Gates Foundation SAN DIEGO , March 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience , Inc.
View HTML
Toggle Summary Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference
SAN DIEGO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will participate in the 30th Annual ROTH Conference on Monday,
View HTML
Toggle Summary Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer, will participate in the LD Micro Virtual Conference on Tuesday, March 6,
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
Company fulfills financing requirement under terms of agreement with Strategic Science & Technologies, LLC SAN DIEGO , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has met the funding requirement
View HTML
Toggle Summary Daré Bioscience, Inc. to raise approximately $10.25 million
SAN DIEGO , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its common stock and warrants to purchase up to 3.5 million shares of its common stock.  Each share of
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it intends to offer primary shares of its common stock and warrants to purchase shares of its common stock in a public offering.  The offering
View HTML
Toggle Summary Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women's biopharmaceutical company, today announced it has entered into an agreement to license SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder ("FSAD"), from Strategic Science & Technologies, LLC ("SST"). FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal that causes distress or interpersonal difficulty.
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference
SAN DIEGO , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health, today announced that Sabrina Martucci Johnson , President and Chief Executive Officer,
View HTML